<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134379</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000596</org_study_id>
    <nct_id>NCT02134379</nct_id>
  </id_info>
  <brief_title>Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation</brief_title>
  <official_title>Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation: A Pilot Trial of the &quot;Dynamic Thoracic Impedance Bed Rest Test&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Porter, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study proposes to perform measurements of approved thoracic impedance technology
      that will help answer questions in patients with decompensated heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Improved metrics derived from the transthoracic impedance (Z) available from implanted
      Medtronic devices may provide more sensitive indicators of the state of compensation for
      heart failure patients. Quantification of specific data may provide new information that can
      improve quality of life for patients and offer vital information to clinicians regarding the
      adequacy of inpatient and outpatient assessment and management of acute decompensated heart
      failure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from sitting to supine to standing in thoracic impedance</measure>
    <time_frame>Baseline, 30 Days</time_frame>
    <description>thoracic impedance will be measured at each position at baseline visit then again at the follow-up visits through 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change in thoracic impedance</measure>
    <time_frame>Baseline, 30 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>Heart Failure; With Decompensation</condition>
  <arm_group>
    <arm_group_label>Heart Failure</arm_group_label>
    <description>Subjects have implanted Medtronic device and a primary diagnosis of left ventricular systolic dysfunction</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic ICDs, CRT-Ds, and CRT-Ps</intervention_name>
    <description>Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.</description>
    <arm_group_label>Heart Failure</arm_group_label>
    <other_name>ICDs:</other_name>
    <other_name>Evera(TM) XT DR (Models DDBB1D4, DDBB1D1)</other_name>
    <other_name>Evera(TM) XT VR (Models DVBB1D4, DVBB1D1)</other_name>
    <other_name>Protecta(R) XT DR (Models D314DRG, D314DRM)</other_name>
    <other_name>Protecta(R) XT VR (Models D314VRG, D314VRM)</other_name>
    <other_name>Secura(R) DR (Models D224DRG, D204DRM)</other_name>
    <other_name>Secura(R) VR (Models D224VRC, D204VRM)</other_name>
    <other_name>Virtuoso(R) II DR (Model D274DRG)</other_name>
    <other_name>Virtuoso(R) II VR (Model D274VRC)</other_name>
    <other_name>Virtuoso(R) DR (Model D154AWG)</other_name>
    <other_name>Virtuoso(R) VR (Model D154VWC)</other_name>
    <other_name>CRT-Ds/CRT-Ps:</other_name>
    <other_name>Viva(TM) XT CRT-D (Models DTBA1D1, DTBA1D4)</other_name>
    <other_name>Viva(TM) S CRT-D (Models DTBB1D1, DTBB1D4)</other_name>
    <other_name>InSync Sentry(R) CRT-D (Models 7297, 7299)</other_name>
    <other_name>Protecta(R) XT CRT-D (Models D314TRM, D314TRG)</other_name>
    <other_name>Concerto(R) II CRT-D (Model D274TRK)</other_name>
    <other_name>Consulta(R) CRT-D (Models D204TRM, D224TRK)</other_name>
    <other_name>Concerto(R) CRT-D (Models C154DWK, C164AWK)</other_name>
    <other_name>Consulta(R) CRT-P (Model C4TR01)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be identified from the KU Hospital Cardiology clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with systolic dysfunction

          -  Able to provide informed consent

          -  Have a Medtronic manufactured device with Thoracic Impendence Monitoring capabilities

        Exclusion Criteria:

          -  Patients with severe congestive heart failure who are intubated

          -  Patients who are oxygen dependent on continuous positive or bilevel positive
             ventilation

          -  Inability to tolerate postural variations due to congestive heart failure or other
             medical or surgical condition.Unable to complete proposed testing

          -  Subjects who cannot giveWill not give written, informed consent on their own behalf
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Porter, MD, FACC, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Charles Porter, MD</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Thoracic Impedance</keyword>
  <keyword>Diagnostic Marker</keyword>
  <keyword>Bed Rest Test</keyword>
  <keyword>Transthoracic Impedance</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>HF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

